WaveMan
WaveMan · Company
MGX · Metagenomi Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

MGX Metagenomi Therapeutics (MGX) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001785279
Quote by TradingView
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
14
13F, latest reported quarter

What the filings say about MGX

Insiders, 180 days
+$9.0K net bought
1 buyer · 3 sellers · 0% of sales under a 10b5-1 plan

Metagenomi Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Metagenomi Therapeutics, Inc. insiders bought a net $9.0K of stock across 30 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Reid Laurence
Director
BUY
2026-09-11 SECtraded 2026-09-09
19,883
$23.3K
-35.5%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 100.0% of the 19,883 shares held after it.
  • No other insider bought within 30 days.
  • 14 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Reid Laurence bought about $23.3K of MGX on Sep 9, 2026, the largest insider purchase at the company since 2024; 14 funds added in the latest 13F quarter.
Reid Laurence
Director
BUY
2026-09-11 SECtraded 2026-09-09
117
$138
-35.5%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 0.6% of the 20,000 shares held after it.
  • No other insider bought within 30 days.
  • 14 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Reid Laurence bought about $138 of MGX on Sep 9, 2026, the largest insider purchase at the company since 2024; 14 funds added in the latest 13F quarter.
Wapnick Pamela
Chief Financial Officer
SELL
2026-09-10 SECtraded 2026-09-08
1,911
$2.2K
-33.9%
Context
  • 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on Jun 5, 2026.
  • The trade is 0.9% of the 206,580 shares held after it.
  • 2 other insiders sold within 30 days.
  • 14 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Wapnick Pamela sold about $2.2K of MGX on Sep 8, 2026; 2 other insiders sold within 30 days and 14 funds added in the latest 13F quarter.
Irish Jian
See Remarks
SELL
2026-09-10 SECtraded 2026-09-08
2,140
$2.5K
-33.9%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Jun 5, 2026.
  • The trade is 0.6% of the 375,393 shares held after it.
  • 2 other insiders sold within 30 days.
  • 14 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Irish Jian sold about $2.5K of MGX on Sep 8, 2026; 2 other insiders sold within 30 days and 14 funds added in the latest 13F quarter.
Wein Matthew
See Remarks
SELL
2026-09-10 SECtraded 2026-09-08
358
$415
-33.9%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Jun 5, 2026.
  • The trade is 0.3% of the 126,133 shares held after it.
  • 2 other insiders sold within 30 days.
  • 14 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Wein Matthew sold about $415 of MGX on Sep 8, 2026; 2 other insiders sold within 30 days and 14 funds added in the latest 13F quarter.
30 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 25 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$9.0K over 180 days
+$18.3K over 90 days
more than 66% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
14 funds bought in last quarter
below 75% of Pharma & Biotech
Revenue
-51.8% year over year
below 81% of Pharma & Biotech
Margin
-348.5% net margin
below 74% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
5.0% of the float short (float per yahoo 2026-10-26) · 10.5 days to cover · settled 2026-09-30
below 58% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch MGX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-72.4%12M
-72%-47%-21%+4%2025-102025-122026-022026-042026-062026-082026-10 2026-09-09 · Reid Laurence bought $23.3K2025-12-05 · Thomas Brian C. sold $6.8K2026-06-05 · Irish Jian sold $4.9K2026-06-05 · Wapnick Pamela sold $3.7K2025-12-05 · Irish Jian sold $2.8K2025-12-05 · Wapnick Pamela sold $2.8K2026-03-05 · Irish Jian sold $2.6K2026-03-05 · Wapnick Pamela sold $2.5K2026-09-08 · Irish Jian sold $2.5K2026-09-08 · Wapnick Pamela sold $2.2K2026-03-05 · Wein Matthew sold $7712026-06-05 · Wein Matthew sold $7252026-09-08 · Wein Matthew sold $4152025-12-05 · Wein Matthew sold $3522026-09-09 · Reid Laurence bought $138
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns MGX: institutional holders (13F)

13F holdings, latest reported quarter
VANGUARD CAPITAL MANAGEMENT LLC
1,077,700 sh
$1.3M
RENAISSANCE TECHNOLOGIES LLC
742,400 sh
$883.5K
Catalio Capital Management, LP
528,993 sh
$629.5K
Peapod Lane Capital LLC
525,024 sh
$624.8K
TWO SIGMA INVESTMENTS, LP
513,701 sh
$611.3K

Congress trades in MGX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

MGX planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

MGX mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Fund
$389.2K position · as of 2026-06-30
0.4%
Ultra-Small Company Market Fund
$74.0K position · as of 2026-06-30
0.0%
iShares Micro-Cap ETF
$113.6K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$8.2K position · as of 2026-06-30
0.0%
Spectrum Fund
$6.5K position · as of 2026-06-30
0.0%
Fidelity Extended Market Index Fund
$257.2K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $9.0K bought by insiders over 180 days, 14 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

MGX financials

Revenue growth
-51.8%
XBRL, annual
Net margin
-348.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$22.3M
four quarters, 2025-04-01 to 2026-03-31
Net margin, TTM
-418.5%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$85.8M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-60.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-41.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-52.2%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-296.1%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-12
Revenue$25.2M$52.3M$44.8M
Operating income-$96.0M-$88.9M-$78.5M
Net income-$87.9M-$78.1M-$68.3M
EPS (diluted)-2.36-2.36-20.05
Operating cash flow-$88.9M-$109.1M-$91.4M
Cash$41.7M$27.4M$140.6M
SEC XBRL, fiscal years, as known on 2026-10-28

MGX Stock Sonar score 5/7 axes

Find similar shapesCompare

MGX ranks highest on insider conviction (61st percentile) and risk and compliance (53rd), and lowest on growth (19th), among Pharma & Biotech peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
49
Inputs
  • Return on equity-60.6% · 47 pct, sector of 545
  • Return on assets-41.9% · 51 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-52.2% · 48 pct, sector of 576
Growth
19
Inputs
  • Revenue growth, YoY-51.8% · 19 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
61
Inputs
  • Net Form 4 buying (codes P and S), 180d$9K · 65 pct, sector of 428
  • Insider buyers, 180d1 · 56 pct, sector of 437
Institutional and government
25
Inputs
  • Funds adding, latest quarter14 · 25 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
53
Inputs
  • Short interest, % of float+5.0% · 58 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+11.1% · 48 pct, sector of 511
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

MGX filings, in plain words

Are Metagenomi Therapeutics insiders buying or selling MGX?

In the 180 days to 2026-10-28, Metagenomi Therapeutics insiders were net buyers, a net $9.0K: $23.4K of purchases and $14.4K of sales reported on Form 4, by 1 buyer and 3 sellers.

Read the full summary

In the 180 days to 2026-10-28, Metagenomi Therapeutics insiders were net buyers of MGX, a net $9.0K across purchases and sales reported on Form 4 by 1 buyer and 3 sellers. None of the 6 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies